Artritis reumatoide: Tratamiento

  1. Morán Álvarez, P. 1
  2. Arroyo Palomo, J. 1
  3. Revenga Martínez, M. 2
  4. Bachiller Corral, F.J. 2
  5. Vázquez Díaz, M. 1
  1. 1 Servicio de Reumatología. Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS). Hospital Universitario Ramón y Cajal. Madrid. España
  2. 2 Servicio de Reumatología. Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS). Hospital Universitario Ramón y Cajal. Madrid. España Departamento de Medicina y Especialidades Médicas. Universidad de Alcalá. Alcalá de Henares. Madrid. España
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2021

Serie: 13

Número: 30

Páginas: 1681-1693

Tipo: Artículo

DOI: 10.1016/J.MED.2021.03.028 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

La artritis reumatoide es una enfermedad inflamatoria crónica sistémica que se caracteriza por una inflamación poliarticular que causa la aparición de erosiones óseas y disfunción articular. Hoy en día, para su tratamiento disponemos de fármacos modificadores de la enfermedad (FAME) sintéticos y biológicos. El objetivo con estos pacientes debe ser alcanzar la remisión o, en su defecto, la baja actividad de la enfermedad, siguiendo la estrategia treat-to-target.

Referencias bibliográficas

  • Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54(3): 692-701.
  • Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017;76(1):17-28.
  • Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685-699.
  • Sanmartí R, García Rodríguez S, Álvaro Gracia JM, Andreu JL, Balsa A, Cáliz R, 2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis. Reumatol Clin. 2015;11(5):279-294.
  • Strehl C, Bijlsma JW, de Wit M, Boers M, Caeyers N, Cutolo M, Defining conditions where long term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing re-commendations: viewpoints from an EULAR task force. Ann Rheum Dis. 2016;75(6):952-957.
  • Hardy RS, Raza K, Cooper MS. Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseases. Nat Rev Rheumatol. 2020;16(3): 133-144.
  • Schiff MH, Jaffe JS, Freundlich B. Head to head randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug exposure limitations of oral methotrexate at doses ≥ 15 mg may be overcome with subcutaneous administration. Ann Rheum Dis. 2014;73:1549-1551.
  • Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, et al. Two year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum. 2001;44(9):1984-1992.
  • Scott DL, Smolen JS, Kalden JR, van de Putte LB, Larsen A, Kvien TK, Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis. 2001;60(10):913-923.
  • Smolen JS, Emery P, Kalden JR, Van Riel PL, Dougados M, Strand CV, The efficacy of leflunomide monotherapy in rheumatoid arthritis: towards the goals of disease modifying antirheumatic drug therapy. J Rheumatol Suppl. 2004;71:13-20.
  • Cutolo M, Bolosiu H, Perdriset G; LEADER Study Group. Efficacy and safety of leflunomide in DMARD naive patients with early rheumatoid arthritis: comparison of a loading and a fixed dose regimen. Rheumatology (Oxford). 2013;52(6):1132-1140.
  • Jorge AM, Melles RB, Zhang Y, Lu N, Rai SK, Young LH, Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines. Arthritis Res Ther. 2018;20(1):133.
  • Kerschbaumer A, Sepriano A, Smolen JS, van der Heijde D, Dougados M, van Vollenhoven R, Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2020;79:744-759.
  • Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76:960-977.
  • Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354:1932-1399.
  • Smolen JS, Van Der Heijde DM, St Clair EW, Emery P, Bathon JM, Keystone E, Predictors of joint damage in patients with early rheumatoid arthritis treated with high dose methotrexate with or without concomitant infliximab: results from the ASPIRE trial. Arthritis Rheum. 2006;54:702-710.
  • Goekoop Ruiterman YP, De Vries Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. Arthritis Rheum. 2005;52:3381-3390.
  • Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Adalimumab, a fully human anti tumour necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003;48:35-45.
  • Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, The PREMIER study: a multicenter, randomized, doublé blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26-37.
  • van der Heijde D, Klareskog L, Rodríguez Valverde V, Codreanu C, Bolosiu H, Melo Gomes J, Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two year clinical and radiographic results from the TEMPO study, a doublé blind, randomized trial. Arthritis Rheum. 2006;54:1063-1074.
  • van Riel PL, Freundlich B, MacPeek D, Pedersen R, Foehl JR, Singh A; ADORE Study Investigators. Patient reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial. Ann Rheum Dis. 2008;67:1104-1110.
  • Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, doublé blind, parallel treatment trial. Lancet. 2008;372:375-382.
  • Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, et al. Golimumab, a human anti tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate naive patients with active rheumatoid arthritis: twenty four week results of a phase III, multicenter, randomized, doublé blind, placebo controlled study of golimumab before methotrexate as first line therapy for early onset rheumatoid arthritis. Arthritis Rheum. 2009;60(8):2272-2283.
  • Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GOFORWARD Study. Ann Rheum Dis. 2009;68:789-796.
  • Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO AFTER study): a multicentre, randomised, doublé blind, placebo controlled, phase III trial. Lancet. 2009;374(9685):210-221.
  • Keystone E, Heijde D, Mason D Jr, Landewé R, Vollenhoven RV, Combe B, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: fin-dings of a fifty two week, phase III, multicenter, randomized, double blind, placebo controlled, parallel group study. Arthritis Rheum. 2008;58(11): 3319-3329.
  • Smolen JS, Landewé RB, Mease P, Brzezicki J, Mason D, Luijtens K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis. 2009a;68:797-804.
  • Thaler K, Chandiramani DV, Hansen RA, Gartlehner G. Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project. Biologics. 2009;3:485-498.
  • Emery P, Fleischmann R, Filipowicz Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, doublé blind, placebo controlled, dose ranging trial. Arthritis Rheum. 2006;54:1390-1400.
  • Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, Rituximab for rheumatoid arthritis refractory to anti tumour necrosis factor therapy: results of a multicenter, randomized, doublé blind, placebo controlled, phase III trial evaluating primary efficacy and safety at twenty four weeks. Arthritis Rheum. 2006;54:2793-2806.
  • Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud Mendoza C, Effects of abatacept in patients with methotrexate resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2006;144:865-876.
  • Genovese MC, Becher JC, Schiff M, Luggen M, Sherrer Y, Kremer J, Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med. 2005;353(11):1114-1123.
  • Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, Efficacy and safety of abatacept or infliximab vs placebo in AT-TEST: a phase III, multicentre, randomised, doublé blind, placebo controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis. 2008;67:1096-1103.
  • Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gómez Reino JJ, Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBI-TION study. Ann Rheum Dis. 2010;69:88-96.
  • Smolen JS, Beaulieu A, Rubbert Roth A, Ramos Remus C, Rovensky J, Alecock E, Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a doublé blind, placebo controlled, randomised trial. Lancet. 2008;371:987-997.
  • Fleischmann R, Burgos Vargas R, Skopouli FN, Tocilizumab inhibits radiographic progression, improves physical function, and gains efficacy over time: LITHE 2 year. Ann Rheum Dis. 2010;69Suppl3:384.
  • Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, doublé blind, controlled phase 4 trial. Lancet. 2013;381:1541-1550.
  • Strand V, Kosinski M, Chen CI, Joseph G, Rendas Baum R, Graham NM, Sarilumab plus methotrexate improves patient reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. Arthritis Res Ther. 2016;18(1):198.
  • Fleischmann R, van Adelsbert J, Lin Y, Castelar Pinheiro GD, Brzezicki J, Hrycaj P, Sarilumab and nonbiologic disease modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheum. 2017;69:277-290.
  • Burmester GR, Lin Y, Patel R, van Adelsberg J, Mangan EK, Graham NM, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, doublé blind, parallel group phase III trial. Ann Rheum Dis. 2017;76:840-847.
  • Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, Tofacitinib versus Methotrexate in Rheumatoid Arthritis. N Engl J Med. 2014;370; 2377-2386.
  • Fleischmann R, Kremer JM, Cush J, Schulze Koops H, Connell CA, Bradley JD, Placebo controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367:495-507.
  • Burmester GR, Blanco R, Charles Schoeman C, Wollenhaupt J, Zerbini C, Benda B, Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: A randomised phase 3 trial. Lancet. 2013;381:451-460.
  • Van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, García Meijide JA, Wagner S, Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367:508-519.
  • Dougados M, Van Der Heijde D, Chen Y, Greenwald M, Drescher E, Liu J, LB0001 Baricitinib, an Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in patients with active rheumatoid arthritis (RA) and an inadequate response to CDMARD therapy: Results of the phase 3 RA-build study. Ann Rheum Dis. 2015;74:79.
  • Genovese M, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, et al. OP0029 baricitinib, an oral Janus Kinase (JAK)1/JAK2 inhibitor, in patients with active rheumatoid arthritis (RA) and an inadequate response to TNF inhibitors: results of the phase 3 RA-beacon study. Ann Rheum Dis. 2015;74:75-76.
  • Burmester GR, Kremer JM, Bosch FVD, Kivitz A, Bessette L, Li Y, Safety and effcacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease modifying antirheumatic drugs (SELECT-NEXT): A randomised, doublé blind, placebo controlled phase 3 trial. Lancet. 2018;391:2503-2512.
  • Genovese MC, Fleischmann R, Combe B, Hall S, Rubbert Roth A, Zhang Y, Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease modifying antirheumatic drugs (SELECT BEYOND): A doublé blind, randomised controlled phase 3 trial. Lancet. 2018;391:2513-2524.
  • Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT MONOTHERAPY): A randomised, placebo controlled, doublé blind phase 3 study. Lancet. 2019;393:2303-2311.
  • Grupo de trabajo de la GUIPCAR. Guía de Práctica Clínica para el Manejo de Pacientes con Artritis Reumatoide. Madrid: Sociedad Española de Reumatología; 2019.
  • Götestam Skorpen C, Hoeltzenbein M, Tincani A, Tincani A, Fischer Betz R, Elefant E, The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75(5):795-810.
  • Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single blind randomised controlled trial. Lancet. 2004;364:263-269.
  • Felson DT, Smolen JS, Wells G, Zhang B, van Tuyl LH, Funovits J, American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63:573-586.
  • Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3-15.
  • Sanmartí R, García Rodríguez S, Álvaro García JM, Andreu JL, Balsa A, Cáliz R, 2014 update of the Consensus Statement of the Spanish Society of Rheumatology on the use of biological therapies in rheumatoid arthritis. Reumatol Clin. 2015;11(5):279-294
Fuente de los datos: Dialnet